Peng X, Hu Y, Cai W
BMC Public Health. 2024; 24(1):2753.
PMID: 39385206
PMC: 11463129.
DOI: 10.1186/s12889-024-20091-x.
Chen H, Man Hoi M, Lee S
Chin Med. 2024; 19(1):56.
PMID: 38532487
PMC: 10967063.
DOI: 10.1186/s13020-024-00884-3.
Xiao Y, Yin S, Bai Y, Wang J, Cui J, Yang Y
Front Nutr. 2024; 10:1329687.
PMID: 38370980
PMC: 10870421.
DOI: 10.3389/fnut.2023.1329687.
Ononye R, Mistry L
Cureus. 2023; 15(11):e48388.
PMID: 37937180
PMC: 10627526.
DOI: 10.7759/cureus.48388.
Abrar S, Mohsin R, Samad A
Pak J Med Sci. 2023; 39(3):667-671.
PMID: 37250566
PMC: 10214798.
DOI: 10.12669/pjms.39.3.6313.
Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?.
Kinjo M, Masuda K, Nakamura Y, Taguchi S, Tambo M, Fukuhara H
Int Urogynecol J. 2022; 34(4):853-859.
PMID: 35699775
DOI: 10.1007/s00192-022-05261-y.
Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study.
Kachru N, Holmes H, Johnson M, Chen H, Aparasu R
Curr Med Res Opin. 2021; 37(8):1303-1313.
PMID: 33890538
PMC: 9289997.
DOI: 10.1080/03007995.2021.1920899.
Urgency urinary incontinence, loss of independence, and increased mortality in older adults: A cohort study.
Yoshioka T, Kamitani T, Omae K, Shimizu S, Fukuhara S, Yamamoto Y
PLoS One. 2021; 16(1):e0245724.
PMID: 33471838
PMC: 7817052.
DOI: 10.1371/journal.pone.0245724.
Factors Influencing Lower Urinary Tract Symptoms in Advanced Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy.
Cho O, Yoo Y, Kim J, Park R, Hwang K
Int Neurourol J. 2018; 22(3):192-199.
PMID: 30286582
PMC: 6177728.
DOI: 10.5213/inj.1836084.042.
Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials.
Arruda R, Takano C, Batista Castelo Girao M, Haddad J, Aleixo G, Castro R
Rev Bras Ginecol Obstet. 2018; 40(4):225-231.
PMID: 29747213
PMC: 10316908.
DOI: 10.1055/s-0038-1642631.
Overactive Bladder Syndrome: Evaluation and Management.
Leron E, Weintraub A, Mastrolia S, Schwarzman P
Curr Urol. 2018; 11(3):117-125.
PMID: 29692690
PMC: 5903463.
DOI: 10.1159/000447205.
Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study.
Tadrous M, Elterman D, Khuu W, Mamdani M, Juurlink D, Gomes T
Can Urol Assoc J. 2018; 12(3):E142-E145.
PMID: 29319477
PMC: 5869040.
DOI: 10.5489/cuaj.4541.
Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.
Kaye J, Margulis A, Fortuny J, McQuay L, Plana E, Bartsch J
Pharmacotherapy. 2017; 37(6):673-683.
PMID: 28370075
PMC: 5518180.
DOI: 10.1002/phar.1932.
Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder.
Kachru N, Sura S, Chatterjee S, Aparasu R
Drugs Aging. 2016; 33(10):755-763.
PMID: 27681701
DOI: 10.1007/s40266-016-0399-5.
Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study.
Goranitis I, Barton P, Middleton L, Deeks J, Daniels J, Latthe P
PLoS One. 2016; 11(8):e0160351.
PMID: 27513926
PMC: 4981306.
DOI: 10.1371/journal.pone.0160351.
Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies.
Faithfull S, Lemanska A, Aslet P, Bhatt N, Coe J, Drudge-Coates L
Int J Clin Pract. 2015; 69(10):1184-208.
PMID: 26292988
PMC: 5042099.
DOI: 10.1111/ijcp.12693.
Refractory overactive bladder: a common problem?.
Schwantes U, Grosse J, Wiedemann A
Int Urogynecol J. 2015; 26(10):1407-14.
PMID: 25792353
PMC: 4575380.
DOI: 10.1007/s00192-015-2674-0.
Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
Huang W, Zong H, Zhou X, Zhang Y
Int Urol Nephrol. 2015; 47(3):457-64.
PMID: 25636812
DOI: 10.1007/s11255-015-0916-1.
Mirabegron: a Beta-3 agonist for overactive bladder.
Bragg R, Hebel D, Vouri S, Pitlick J
Consult Pharm. 2014; 29(12):823-37.
PMID: 25521658
PMC: 4605389.
DOI: 10.4140/TCP.n.2014.823.
Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Ju R, Garrett J, Wu J
Int Urogynecol J. 2013; 25(4):479-84.
PMID: 24158462
DOI: 10.1007/s00192-013-2246-0.
